BioCardia Inc (BCDA)
2.26
+0.12
(+5.85%)
USD |
NASDAQ |
Nov 22, 16:00
2.27
+0.01
(+0.44%)
After-Hours: 20:00
BioCardia Cash from Financing (Quarterly): 6.122M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.122M |
| June 30, 2024 | 1.787M |
| March 31, 2024 | 1.376M |
| December 31, 2023 | 1.119M |
| September 30, 2023 | -0.058M |
| June 30, 2023 | 2.601M |
| March 31, 2023 | 0.064M |
| December 31, 2022 | 3.695M |
| September 30, 2022 | 0.073M |
| June 30, 2022 | 1.354M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.008M |
| June 30, 2021 | -0.066M |
| March 31, 2021 | 2.005M |
| December 31, 2020 | 17.43M |
| September 30, 2020 | -0.067M |
| June 30, 2020 | 10.85M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -0.067M |
| September 30, 2019 | 9.885M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 3.799M |
| September 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.005M |
| December 31, 2017 | 0.118M |
| September 30, 2017 | 0.004M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.022M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.067M
Minimum
Dec 2019
17.43M
Maximum
Dec 2020
2.411M
Average
0.596M
Median
Cash from Financing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 102.76M |
| The Cooper Companies Inc | -87.60M |
| Theriva Biologics Inc | 3.716M |
| Zevra Therapeutics Inc | 64.76M |
| Instil Bio Inc | 0.159M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.611M |
| Cash from Investing (Quarterly) | -0.002M |
| Free Cash Flow | -7.309M |
| Free Cash Flow Per Share (Quarterly) | -0.9241 |
| Free Cash Flow Yield | -164.1% |